Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

23andMe Turns To Drug Discovery

by Rick Mullin
March 23, 2015 | A version of this story appeared in Volume 93, Issue 12

23andMe, a pioneer in providing personal DNA screening, now plans to pursue drug discovery. The effort will be run by Richard Scheller, the former head of research and early development at Genentech. 23andMe has made significant changes to its business plan following a 2013 FDA determination that its Personal Genome Service is a diagnostic requiring agency approval. Over the past two years, the company has pursued drug discovery partnerships, including one with Genentech to analyze genomics data for Parkinson’s disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.